Abstract
Background
Understanding of treatment response to biologic therapy for severe asthma in the real world remains
limited.
Objective
To examine multiple levels of response to biologic therapy in adults with severe asthma in ISAR.
Methods
This multi-country (n=23), registry-based study included patients ≥18 years who initiated biologics (antiIL5/5R, anti-IgE, anti-IL4/IL13). Response in the 12 months (min. 6 months) post-initiation among impaired
patients (as defined in Figure 1) was assessed as: ≥50% reduction in exacerbation rate, ≥50% reduction in LTOCS daily dose, ≥1 level improvement in asthma control, and ≥100 mL increase in FEV1, alone or in
combination of 2,3, 4 endpoints.
Results
Of total 1986 eligible adults, median age was 54 years, 59.7% were female; 79.7%, 53.6%, 47.4%, and
53.1% of patients achieved response in exacerbation, LTOCS, asthma control, and FEV1, respectively.
Treatment response ranged from 43.6% to 10.5% when extending the definition from 2 to 4 endpoints.
Greater response was observed in patients treated with anti-IL5/5R and anti-IL4/IL13 (Figure 1).
Conclusion
Biologic effectiveness is evidenced as a large proportion of patients achieved response in at least one
endpoint. There is still unmet need as the majority were non-responders in composite 4 endpoints.
Response varies by definition, thus, multiple endpoints should be considered to fully assess response to
biologics.
Understanding of treatment response to biologic therapy for severe asthma in the real world remains
limited.
Objective
To examine multiple levels of response to biologic therapy in adults with severe asthma in ISAR.
Methods
This multi-country (n=23), registry-based study included patients ≥18 years who initiated biologics (antiIL5/5R, anti-IgE, anti-IL4/IL13). Response in the 12 months (min. 6 months) post-initiation among impaired
patients (as defined in Figure 1) was assessed as: ≥50% reduction in exacerbation rate, ≥50% reduction in LTOCS daily dose, ≥1 level improvement in asthma control, and ≥100 mL increase in FEV1, alone or in
combination of 2,3, 4 endpoints.
Results
Of total 1986 eligible adults, median age was 54 years, 59.7% were female; 79.7%, 53.6%, 47.4%, and
53.1% of patients achieved response in exacerbation, LTOCS, asthma control, and FEV1, respectively.
Treatment response ranged from 43.6% to 10.5% when extending the definition from 2 to 4 endpoints.
Greater response was observed in patients treated with anti-IL5/5R and anti-IL4/IL13 (Figure 1).
Conclusion
Biologic effectiveness is evidenced as a large proportion of patients achieved response in at least one
endpoint. There is still unmet need as the majority were non-responders in composite 4 endpoints.
Response varies by definition, thus, multiple endpoints should be considered to fully assess response to
biologics.
| Original language | English |
|---|---|
| Number of pages | 4 |
| Publication status | Published - 15 Jun 2023 |
| Event | ERS 2023 International Congress - Duration: 7 Sept 2023 → 13 Sept 2023 https://www.ersnet.org/congress-and-events/congress/ |
Conference
| Conference | ERS 2023 International Congress |
|---|---|
| Period | 7/09/23 → 13/09/23 |
| Internet address |